Bioasis Technologies (BIOAF) 1.1284 $BIOAF
biOasis Provides Scientific Updates on Its Transcend Programs
Marketwired - Tue May 12, 6:00PM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.
BTI.VN: 1.350 (-0.020)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Pipeline Report 2015 - 8 Companies & 10 Drug Profiles
M2 - Mon Apr 27, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7z8r66/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ArmaGen Technologies, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Sangamo BioSciences, Inc. - Shire Plc - Synageva BioPharma Corp. Drug Profiles - AGT-182 - FT-1050 - Gene Therapy to Target Iduronate 2-Sulfatase for Hunter Syndrome - idursulfase - idursulfase - JR-032 - MTf-I2S - MTfp-I2S - Next Generation biologics for Pompe, Fabry and Hunter - SHP-631 For more information visit http://www.researchandmarkets.com/research/7z...saccharido
FATE: 6.80 (-0.12), GEVA: 211.50 (-1.10), SHPG: 254.45 (+3.99), SGMO: 11.51 (unch)
biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease in The Brain
Marketwired - Tue Apr 21, 4:01PM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces that the European Patent for the use of Transcend to deliver enzymes to treat Lysosomal Storage Disease to the brain has now been fully issued and has cleared the "Notice of Opposition" period.
BTI.VN: 1.350 (-0.020)
biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score
Marketwired - Mon Mar 16, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the results from an animal ischemic stroke model performed at the National Research Council Canada with the biOasis Transcend carrier peptide, MTfp and siRNA (MTfp-siRNA). Two key therapeutic effects were shown with MTfp-siRNA; A high degree of reduction of the area of blood vessel infarct and improvement of overall brain activity as determined by neurological scoring.
BTI.VN: 1.350 (-0.020)
biOasis awards stock options at a price of USD1.17 per optioned share
M2 - Mon Feb 02, 6:40AM CST
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(BIOAF) declared on Friday that it has granted an aggregate of 1,215,000 incentive stock options (stock options) to directors, officers, consultants and employees under its Stock Option Plan and subject to the policies of the TSX Venture Exchange.
BTI.VN: 1.350 (-0.020)
biOasis Announces Grant of Stock Options
Marketwired - Fri Jan 30, 7:31PM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company"
wishes to announce that it has granted an aggregate of 1,215,000 incentive stock options (the "Stock Options" to directors, officers, consultants and employees of the Company pursuant to the Company's Stock Option Plan, subject to the policies of the TSX Venture Exchange. The Stock Options are exercisable at a price of $1.17 per optioned share for a period of five years. 965,000 of the Stock Options shall vest over a period of one year and 250,000 of the Stock Options shall vest over a period of two years.
BTI.VN: 1.350 (-0.020)
biOasis Announces the Release of an Analyst Report
Marketwired - Tue Jan 20, 4:25PM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company" wishes to announce the release of an analyst report (the "Report" providing a synopsis of the Company. Mr. Jim Darcel, www.jrstocks.com, prepared the Report.
BTI.VN: 1.350 (-0.020)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 6.80 (-0.12), GEVA: 211.50 (-1.10), SGMO: 11.51 (unch), FOLD: 10.53 (+0.03), CUR: 1.70 (-0.04)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 6.80 (-0.12), OPK: 16.92 (+0.24), PTCT: 52.09 (-2.24), ATHX: 1.27 (-0.01), FOLD: 10.53 (+0.03)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 6.80 (-0.12), SHPG: 254.45 (+3.99)
biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
Marketwire - Tue Oct 07, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF) (TSX VENTURE: BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB" , engages Willow Tree Capital Group of Toronto, Canada. Willow Tree's full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies worldwide. With its broad transactional experience, Willow Tree specializes in Licensing, strategic consultation and Mergers & Acquisitions services, employing industry-recognized valuation models for life science market value assessments.
BTI.VN: 1.350 (-0.020)
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Marketwire - Thu Sep 18, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB" , announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B" of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the "Diagnosis and Therapy of Lysosomal Disorders" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin.
BTI.VN: 1.350 (-0.020)
biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC" , will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease.
BTI.VN: 1.350 (-0.020)
biOasis Provides Scientific Updates on Its Transcend Programs
Marketwired - Tue May 12, 6:00PM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.
BTI.VN: 1.350 (-0.020)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Pipeline Report 2015 - 8 Companies & 10 Drug Profiles
M2 - Mon Apr 27, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7z8r66/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ArmaGen Technologies, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Sangamo BioSciences, Inc. - Shire Plc - Synageva BioPharma Corp. Drug Profiles - AGT-182 - FT-1050 - Gene Therapy to Target Iduronate 2-Sulfatase for Hunter Syndrome - idursulfase - idursulfase - JR-032 - MTf-I2S - MTfp-I2S - Next Generation biologics for Pompe, Fabry and Hunter - SHP-631 For more information visit http://www.researchandmarkets.com/research/7z...saccharido
FATE: 6.80 (-0.12), GEVA: 211.50 (-1.10), SHPG: 254.45 (+3.99), SGMO: 11.51 (unch)
biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease in The Brain
Marketwired - Tue Apr 21, 4:01PM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces that the European Patent for the use of Transcend to deliver enzymes to treat Lysosomal Storage Disease to the brain has now been fully issued and has cleared the "Notice of Opposition" period.
BTI.VN: 1.350 (-0.020)
biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score
Marketwired - Mon Mar 16, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the results from an animal ischemic stroke model performed at the National Research Council Canada with the biOasis Transcend carrier peptide, MTfp and siRNA (MTfp-siRNA). Two key therapeutic effects were shown with MTfp-siRNA; A high degree of reduction of the area of blood vessel infarct and improvement of overall brain activity as determined by neurological scoring.
BTI.VN: 1.350 (-0.020)
biOasis awards stock options at a price of USD1.17 per optioned share
M2 - Mon Feb 02, 6:40AM CST
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(BIOAF) declared on Friday that it has granted an aggregate of 1,215,000 incentive stock options (stock options) to directors, officers, consultants and employees under its Stock Option Plan and subject to the policies of the TSX Venture Exchange.
BTI.VN: 1.350 (-0.020)
biOasis Announces Grant of Stock Options
Marketwired - Fri Jan 30, 7:31PM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company"
wishes to announce that it has granted an aggregate of 1,215,000 incentive stock options (the "Stock Options" to directors, officers, consultants and employees of the Company pursuant to the Company's Stock Option Plan, subject to the policies of the TSX Venture Exchange. The Stock Options are exercisable at a price of $1.17 per optioned share for a period of five years. 965,000 of the Stock Options shall vest over a period of one year and 250,000 of the Stock Options shall vest over a period of two years. BTI.VN: 1.350 (-0.020)
biOasis Announces the Release of an Analyst Report
Marketwired - Tue Jan 20, 4:25PM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company"
wishes to announce the release of an analyst report (the "Report" providing a synopsis of the Company. Mr. Jim Darcel, www.jrstocks.com, prepared the Report. BTI.VN: 1.350 (-0.020)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 6.80 (-0.12), GEVA: 211.50 (-1.10), SGMO: 11.51 (unch), FOLD: 10.53 (+0.03), CUR: 1.70 (-0.04)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 6.80 (-0.12), OPK: 16.92 (+0.24), PTCT: 52.09 (-2.24), ATHX: 1.27 (-0.01), FOLD: 10.53 (+0.03)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 6.80 (-0.12), SHPG: 254.45 (+3.99)
biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
Marketwire - Tue Oct 07, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF) (TSX VENTURE: BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB"
, engages Willow Tree Capital Group of Toronto, Canada. Willow Tree's full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies worldwide. With its broad transactional experience, Willow Tree specializes in Licensing, strategic consultation and Mergers & Acquisitions services, employing industry-recognized valuation models for life science market value assessments. BTI.VN: 1.350 (-0.020)
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Marketwire - Thu Sep 18, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB"
, announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B" of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the "Diagnosis and Therapy of Lysosomal Disorders" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin. BTI.VN: 1.350 (-0.020)
biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC"
, will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease. BTI.VN: 1.350 (-0.020)
